Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. simecos

Simecos SIGNED

A New Adjuvant Nutraceutical from the North Atlantic Ocean for Breast, Lung and Pancreatic Cancer Patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 Simecos project word cloud

Explore the words cloud of the Simecos project. It provides you a very rough idea of what is the project "Simecos" about.

market    prove    pay    marine    biotechnology    cancer    purified    clinical    exoskeleton    therapeutic    inhibition    investment    expansion    18m    adjuvant    worsen    entail    pain    iceland    9    82    ouml    tumour    profit    rates    shrimp    vitro    extracted    rdur    fishery    optimise    compounds    treatment    biological    chitinase    chitooligosaccharides    95    2002    effect    validate    feasibility    effectiveness    fishing    clinically    diseases    give    human    simecos    atlantic    opportunity    45m    780    fatigue    genis    20    molecules    considering    solutions    quality    inflammation    2    2008    30    started    anti    2020    industry    hence    supplements    pancreatic    siglufj    health    discovered    decrease    proven    business    forefront    vivo    patients    ph2    village    north    enzyme    lung    respectively    trial    trade    chos    complementary    breast    chitin    diagnosed    chemotherapy    life    nutraceutical    thanks    ykl    manufacturing    inflammatory    crisis    2024    survival    return    levels    roi    confirmed    budget    validated    ph1   

Project "Simecos" data sheet

The following table provides information about the project.

Coordinator		 GENIS HF 

Organization address
address: ADALGOTU 34
city: SIGLUFJORDUR
postcode: 580
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Iceland [IS]
 Project website https://simecos.benecta.is
 Total cost 2˙180˙387 €
 EC max contribution 1˙526˙271 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENIS HF IS (SIGLUFJORDUR) coordinator 1˙526˙271.00

Map

 Project objective

Genis is based in Siglufjördur, a village in the North Iceland traditionally focused on the fishing industry. After the fishery crisis worsen in 2008, Siglufjördur started to pay attention to the marine biotechnology, with Genis at the forefront. Hence, since 2002, we develop health products based in T-ChOS™ (Therapeutic Chitooligosaccharides), which are compounds obtained from chitin extracted from the North Atlantic shrimp exoskeleton. T-ChOS™ show a strong anti-inflammatory effect based in a novel biological pathway discovered by Genis: Inhibition of the YKL-40 chitinase enzyme, whose levels are very high in several diseases as cancer. Our in vitro, in vivo and human studies prove that T-ChOS™ can decrease inflammation and enhance tumour response to chemotherapy. During the Ph1 project, we confirmed the feasibility of developing a nutraceutical based on T-ChOS™ to use as an adjuvant to chemotherapy in cancer patients. In this Ph2 project, we aim to optimise manufacturing, validate through a clinical trial and bring to market SIMECOS: A nutraceutical for cancer patients derived from chitin purified T-ChOS™ molecules. SIMECOS targets lung, breast and pancreatic cancer patients, with survival rates after 5-year of 20%, 82.2% and 5.2%, respectively. SIMECOS is expected to increase their quality of life, thanks to its proven effects to decrease pain and fatigue. The high trends (30%-95%) among cancer patients to use complementary supplements entail a great business opportunity for SIMECOS as in Europe, there are more than 780,000 patients per year diagnosed with breast, pancreatic and lung cancer looking for solutions to decrease chemotherapy side effects and improve the effectiveness of their treatment. Clinically validated SIMECOS will help these patients. We expect SIMECOS to reach the market in 2020. By 2024, after our European expansion, SIMECOS will give a profit of €10.45M and considering a Phase 2 budget of €2.18M, the return-on-investment (ROI) will be 9.9

 Deliverables

List of deliverables.
SIMECOS web page Websites, patent fillings, videos etc. 2020-03-19 15:44:56

Take a look to the deliverables list in detail:  detailed list of Simecos deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIMECOS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIMECOS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

PICSOHF (2020)

PICSOHF, A minimally invasive cardiac intervention medical device to regenerate a damaged heart and extend the life of patients with Heart Failure

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More